Qingkailing Injection Versus Puerarin Injection on Withdr... | NCT02264301 | Trialant

Qingkailing Injection Versus Puerarin Injection on Withdr... | NCT02264301 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Puerarin injection 400 mg	Active Comparator	Patients under the treatment of Puerarin injection 400 mg,daily,for 24 weeks	Drug: Puerarin injection 400 mg
Qingkailing injection 40 ml	Experimental	Patients under the treatment of Qingkailing injection 40 ml,daily,for 24 weeks	Drug: Qingkailing injection 40 ml

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Change from baseline in corticosteroids withdrawal rate at 24 weeks	The number (rate) of patients who do not need the use of corticosteroids any more were monitored 0 week, 12 weeks, 24 weeks.	At 0 week, 12 weeks, 24 weeks

Secondary Outcomes

Measure	Description	Time Frame
Change from baseline in Disease activity score in 28 joints(DAS28)	Disease activity of RA is assessed using disease activity score in 28 joints (DAS28). DAS28 = 0.56 • √(tender joint count) + 0.28 •√(swollen joint count) + 0.70 In(ESR) + 0.014(global health on visual analogue scale).DAS28 will be assessed at At 0 week, 12 weeks and 24 weeks	At 0 week, 12 weeks, 24 weeks

Contacts/Locations Module

Ancestor Terms

ID	Term
D001168	Arthritis
D007592	Joint Diseases
D009140	Musculoskeletal Diseases
D012216	Rheumatic Diseases
D003240	Connective Tissue Diseases
D017437	Skin and Connective Tissue Diseases
D001327	Autoimmune Diseases
D007154	Immune System Diseases